title: [Experience of weekly paclitaxel combined with orally administered doxifluridine therapy for advanced and recurrent gastric cancer-preliminary study].
abstract: We designed a new regimen to evaluate the efficacy and feasibility of weekly paclitaxel combined with orally administered 5'-DFUR therapy against advanced and recurrent gastric cancer. Nine patients were enrolled. Weekly paclitaxel administration (PTX 60 mg/m2, 2 consecutive weeks, 1-week break) and oral administration of 5'-DFUR (460 mg/m2, 14 consecutive days) were performed on an ambulatory basis. This was repeated every 3 weeks until disease progression and/or severe toxic events occurred. The overall response rate was 44.4% with 22.2% complete response and 22.2% partial response in addition to 44.4% no changes beyond 3 months. In NC criteria, 3 patients showed clinical improvements, such as decreasing tumor markers, releasing from the ileus, and improvement of liver dysfunction. These results suggested that clinical benefits in 89% of patients. On the other hand, toxic events were restricted to grade 3 with 11.1% general fatigue and 11.1% appetite loss. Therefore, the weekly administration of PTX in conjunction with daily oral administration of 5'-DFUR therapy seems to be extremely useful, with excellent anti-tumor effect and tolerable adverse reactions for the treatment of recurrent gastric cancer on an ambulatory basis.
authors.affiliation: Dept. of Surgery, Toyooka Hospital.
authors.forename: Michihiko
authors.initials: M
authors.lastname: Tsubono
authors.forename: Iwao
authors.initials: I
authors.lastname: Kaneko
authors.forename: Eiji
authors.initials: E
authors.lastname: Kii
authors.forename: Toru
authors.initials: T
authors.lastname: Murata
authors.forename: Kazuyasu
authors.initials: K
authors.lastname: Kamimura
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Deguchi
authors.forename: Ryoji
authors.initials: R
authors.lastname: Yasumizu
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D005467:Floxuridine; D017239:Paclitaxel; C025034:doxifluridine